Navigation Links
Winner Medical Reports Second Quarter Fiscal 2011 Results
Date:5/11/2011

SHENZHEN, China, May 11, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: WWIN; "Winner Medical" or the "Company"), a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today reported consolidated financial results for the second quarter ended March 31, 2011.

Second Quarter Fiscal 2011 Highlights

  • Revenue increased by 27% over Q2 FY 2010 to $33.2 million

  • Adjusted net income increased 31% YOY to $3.8 million

  • Adjusted basic EPS increased 23% YOY to $0.16

  • Domestic China sales increased 61% YOY to 8.5 million

  • Sales to North and South America increased 47% YOY to 7.5 million

  • Reiterates FY 2011 revenue guidance of $138-150 million, representing 20%-30% YOY Growth

  • Fiscal Second Quarter and Half Year 2011 Results (in millions of USD, except per share data)Q2
    FY2011

    Q2
    FY2010

    %
    Change

    Six Months
    FY2011

    Six Months
    FY2010

    %
    ChangeNet Sales

    $33.2

    $26.1

    27 %

    $66.9

    $55.9

    20%Cost of Sales

    $23.9

    $18.7

    28%

    $48.1

    $39.1

    23%Gross Profit

    $9.4

    $7.4

    27%

    $18.8

    $16.8

    12%Gross Margin

    28.2%

    28.2%

    -

    28.1%

    30.1%

    (6)%Net Income Attributable to Winner Medical Group Inc.

    $2.2

    $2.7

    (16)%

    $5.6

    $6.6

    (16)%Adjusted Net Income (non-GAAP)*

    $3.8

    $2.9

    31%

    $7.6

    $7.1

    6%EPS (Diluted)

    $0.09

    $0.12

    (25)%

    $0.23

    $0.29

    (21)%Adjusted EPS (Basic, non-GAAP)*

    $0.16

    $0.13

    23%

    $0.31

    $0.32

    (3)%*Excludes non-cash share-based compensation expenses of $0.2 million and $0.2 million and realized loss on commodity financial instruments of $1.3million and $Nil, respectively, for the presentation of figures for the three months ended March 31, 2011 and March 31, 2010. Similarly, for the presentation of figures for the six months ended March 31, 2011 and March 31, 2010, the measures exclude non-cash share-based compensation expenses of $0.5 million and $0.5million and realized loss on commodity financial instruments of $1.5 million and $Nil, respectively. Please see the "Non-GAAP Financial Measures" section below for information on how non-GAAP measures should be viewed in comparison to GAAP measures.Mr. Jianquan Li, Chairman and Chief Executive Officer of Winner Medical, commented: "During the second quarter of fiscal year 2011, sales of our medical products and PurCotton® products in China rapidly increased, signifying robust demand and gains in market share by Winner Medical as we continue to have success penetrating new sales and distribution channels in China and as more Chinese consumers become aware of and accept our products. In addition, the strong sales increase in North and South America reflects local manufacturers continuing to outsource production to China. The Company expects these favorable trends will continue for the near future and support growth in Winner's sales and earnings."

    Mr. Li continued, "Despite rising cotton prices, appreciation of the renminbi, high inflation and higher labor costs in China, the Company still managed to grow gross profit dollars while keeping gross margins flat. We will continue to adjust our business portfolio to carry higher gross margin products and reduce costs where appropriate to offset renminbi appreciation, inflation and rising commodity and labor costs."

    Second Quarter Fiscal 2011 Unaudited Financial ResultsWinner Medical reported net sales of $33.2 million, an increase of 27% compared to the same period last year due to higher pricing and strong reorders of medical and PurCotton products. Sales increased 61% year-over-year in China to $8.5 million, with sales increases in medical products and PurCotton products. Export sales to North and South America remained robust, increasing 47% year-over-year to $7.5 million, driven by increased orders from American and Brazilian clients who recognized Winner Medical's high quality products and timely delivery capabilities. Sales to Japan grew 29% as a result of increased selling prices and volumes. Orders in Europe remained stable year-over-year at $10.6 million, as customers in Britain and Sweden increased purchases while rejected orders from those customers about whom the Company had liquidity concerns as a result of the debt crisis.

    Cost of sales increased 28% to $23.9 million in the second quarter of fiscal 2011, from $18.7 million in the second quarter of fiscal 2010. Cost of sales as a percentage of net revenues were 71.9%, unchanged from the same period last year. To minimize the impact of rising cotton prices, the Company increased its selling prices progressively, implemented lean production methods and purchased cotton futures contracts to hedge against the volatility of cotton prices.

    Gross profit increased 27 % to $9.4 million compared to the second quarter of fiscal 2010. Gross margin was flat at 28.2%. The Company continues to adjust its business portfolio by developing and marketing advanced medical products as well as PurCotton® jumbo rolls and retail products, which carry higher gross margins.

    Selling, general and administrative expenses increased by 40% to $5.8 million in the second quarter of fiscal 2011, from $4.1 million in the same quarter of fiscal 2010. Adjusted selling, general and administrative expenses (non-GAAP), which exclude share-based compensation expenses, were $5.6 million versus $3.9 million for the same period of 2010. The increase was primarily due to higher salary and leasing expenses for the PurCotton retail business.

    The income tax provision for the second quarter of fiscal 2011 was $0.3 million, compared to $0.6 million for the same period in 2010, representing an effective tax rate of 13.4% for this reporting period, versus 19.1% in the same period last year. This decrease was primarily due to the deferred tax asset recognized by the Company for total losses generated by Shanghai Winner Medical Apparatus Co., Ltd.

    Net income attributable to Winner Medical decreased by 16% to $2.2 million, or $0.09 per basic share, compared to net income of $2.7 million, or $0.12 per basic share, for the second quarter of fiscal 2010. This decrease in net income was due to commodity hedging losses. The weighted average diluted shares outstanding were 24.5 million, up 8% year-over-year.

    Excluding the non-cash share-based compensation expenses and realized loss on commodity financial instruments, adjusted net income (non-GAAP) was $3.8 million for the second quarter of fiscal 2011, an increase of 31% from $2.9 million in the same period of 2010. The adjusted basic earnings per share (non-GAAP) was $0.16 for the three months ended March 31, 2011 versus $0.13 per share for the comparable period last year, an increase of 23%.

    Six Months Fiscal 2011 Unaudited Financial ResultsNet sales were $66.9 million, an increase of 20% compared to the same period last year. The increase was mainly attributable to higher average sales prices and increased sales orders from customers in North and South America and from consumers of medical products and PurCotton® products in China.

    Cost of sales increased 23% to $48.1 million, compared to $39.1 million in the same period in fiscal 2010. Cost of sales as a percentage of net revenues were 71.9% and 70.0% for the six months ended March 31 in fiscal 2011 and 2010, respectively. This increase was mainly attributable to increased raw material prices.

    Gross profit increased 12% to $18.8 million compared to the same period in fiscal 2010. Gross margin decreased to 28.1% as compared to 30.1% in the first half of fiscal 2010. The decrease in gross margin was attributable to the increased cost of cotton, the core raw material for the Company, and lower sales of high margin protective medical products, which benefited from the outbreak of H1N1 in the same period last year.

    Selling, general and administrative expenses increased by 25% to $11.9 million during the six months ended March 31, 2011, compared to $9.5 million in the same period of fiscal 2010. Adjusted selling, general and administrative expenses (non- GAAP), which exclude share-based compensation expenses, for this reporting period were $11.3 million, versus $8.9 million for the same period of 2010. The increase was primarily due to higher salary and leasing expenses for PurCotton retail business compared to the same period last year.

    The income tax provision for the six months ended March 31, 2011 was $0.7 million, compared to $1.2 million for the same period in 2010, representing an effective tax rate of 11.4% for this reporting period, versus 15.6% in the same period last year. This decrease was primarily due to the deferred tax asset recognized by the Company for total losses generated by Shanghai Winner Medical Apparatus Co., Ltd.

    Net income attributable to Winner Medical decreased by 16% to $5.6 million, or $0.23 per basic share, compared to net income of $6.6 million, or $0.29  per basic share, for the six months ended March 31, 2010. This decrease in net income during the reporting quarter was mainly due to the realized loss on commodity hedging. The weighted average diluted shares outstanding were 24.5 million, up 8% year-over-year.

    Excluding non-cash share-based compensation expenses and realized loss on commodity financial instruments, adjusted net income (non-GAAP) was $7.6 million for the six months ended March 31, 2011, an increase of 6% from $7.1 million in the same period of 2010. Adjusted basic earnings per share (non-GAAP) was $0.31 for the six months ended March 31, 2011, versus $0.32 per share for the comparable period last year, a decrease of 3%.

    Other Financial HighlightsCash and cash equivalents were $12.0 million as on March 31, 2011 compared to $14.8 million as on September 30, 2010. The Company's working capital as of March 31, 2011 was $47.9 million. Total assets were approximately $134.7 million compared to $119.0 million as of September 30, 2010, while total shareholder's equity was $114.4 million and $105.9 million in the respective periods.

    Second Quarter Fiscal 2011 Operational Updates PurCotton Business Update

    PurCotton sales increased 114% during the second quarter of 2011 to $4.1 million as a result of robust jumbo roll supply and growth of domestic retail business, which are sold in self-operated chain stores, online and in bulk sales to large customers in China.

    Net sales attributable to the PurCotton® jumbo roll-supply business increased to $3.2 million in the three months ended March 31, 2011 from $1.8 million in the same period last year, an increase of 78.3%. This large increase was due to increased demand from Chinese customers who used it as a component in hygiene products. With the increasing demand from these customers, the PurCotton® jumbo roll-supply has been steadily growing.

    Net sales attributable to the PurCotton retail business, which consists of 33 retail stores and online business, increased approximately $0.8 million, to $0.9 million in this reporting period, compared to $0.1 million the same period last year when the Company had only seven PurCotton retail stores and no online business as of the last day of that reporting period.

    As of May 11, 2011, the Company owns and operates 34 PurCotton chain stores in first-tier cities across China, including 9 in Beijing, 4 in Shanghai and 21 in Guangdong province, where the Company's headquarters is located. Six stores were closed due to unsatisfactory performance.In order to build strong awareness of its high-quality and international brand, management believes that Hong Kong will be a good city to launch and promote its PurCotton retail business. The first store in Hong Kong will be opened in mid-May.

    Conducting self-operated stores required higher operating expenses and a longer period of investment turnover when compared with other distribution channels. The Company will focus on efficient operating and developing each existing store, rather than accelerating the pace of store opening. However, self-operated stores are vital for marketing new products and for brand building and will remain an important and significant sales channel for the PurCotton retail business. As of May 11, 2011, approximately 16,000 customer memberships were recorded for the self-operated stores in China.

    In addition, the Company  recently started launching its products into mid-and-high end supermarkets in Shenzhen, particularly the top selling products, such as PurCotton® sanitary napkin and 100% natural cotton tissue. The Company expects that its core products will be launched into more supermarkets and in more cities throughout China in the near future.

    In July 2010, the Company opened its first online PurCotton store at http://purcotton.mall.taobao.com, featuring its entire array of products on Taobao.com, the largest online trading platform in China. In September 2010, the Company also built its own B2C trading website, www.purcotton.com, which is co-branded through its retail stores. Total online customer membership has increased to approximately 29,000 as of May 11, 2011. The Company will continue to leverage and expand its online platform to drive incremental sales of PurCotton retail products.

    Cotton Futures Trading Risk-transferred Agreements

    Cotton is the Company's primary raw material used in its manufacturing process. As a result of rising demand caused by global economic recovery and supply shortages due to bad weather, cotton prices have been rapidly increasing and fluctuating in the last half year. Under this rising cost environment, the Company cannot secure stable price quotes from cotton suppliers, resulting in inconsistency in the prices quoted to the Company's customers. Therefore, the Company, through its wholly-owned subsidiary Winner Industries (Shenzhen) Co., Ltd. ("Winner Shenzhen") has decided to enter into cotton future transactions in order to manage the impact of volatility in cotton prices on production.

    During the second quarter of 2011, Winner Shenzhen's transactions in cotton futures resulted in a net loss of approximately $1,577,000, which was charged to Realized Loss on Commodity Financial Instruments in the condensed consolidated statements of income for the period. The loss was a result of significant increases and fluctuation in cotton prices since January, 2011. During this period, based on management's expectation that cotton prices would experience a downward correction, Winner Shenzhen acquired a short position to hedge against price corrections. However, contrary to management's expectation, the price increase continued. In order to minimize further losses, management closed its short position, generating a loss for the period.

    In order to shift risk away from the Company during the initial period of cotton futures trading and better protect the interests of the Company's shareholders, the chief executive officer of the Company, Mr. Jianquan Li, signed agreements with Winner Shenzhen effective January 1, 2011 that are scheduled to expire on September 30, 2011. Under these agreements, Mr. Jianquan Li agrees that, on September 30, 2011, he will assume all net losses, if any, incurred by Winner Shenzhen from cotton futures trading from January 1, 2011 to September 30, 2011 to the extent of $2,838,000. If, however, there is a net gain from trading activities, it will be retained by Winner Shenzhen.

    Since Winner Shenzhen began trading in cotton futures in October 2010, management has made on-going assessments of its trading performance. As a result of the experience gained over this period, the Company has established more stringent trading procedures and policies, as well as risk-reducing strategies for entering into cotton futures transactions, in regular consultation with the board of directors. Details regarding the loss from trading in cotton futures and the agreements signed by Mr. Jianquan Li are discussed in the "Management's Discussion and Analysis of Financial Condition and Results of Operations—Recent Development" section of the quarterly report on Form 10-Q for the reporting period ended March 31, 2011, as filed with the SEC on May 11, 2011.

    Fiscal Year 2011 Guidance Winner Medical reaffirms its total revenues in fiscal year 2011 to be in the range of $138 million to $150 million, representing a 20-30% year-over-year increase.

    Conference CallWinner Medical's senior management will host a conference call to discuss its second quarter fiscal year 2011 results and recent business developments.

    Date of the conference call: Wednesday, May 11, 2011Time: 08:30 a.m. EDTDial-in Number: +1-800-901-5231 (US)10-800-130-0399 (South China)10-800-852-1490 (North China)400-881-1630 (For China Mobile Users)800-96-3844 (Hong Kong) +1-617-786-2961 (International)Pass code: 56002956A telephone replay will be available shortly after the conclusion of the call and will be accessible from May 11, 2011 at 11:30PM to May 18, 2011 by calling +1-888-286-8010 (US) or +1-617-801-6888 (International) with the pass code 55727684. The earning release will also be available on the investor relations page of Winner Medical' website at http://winnermedical.investorroom.com/ on Thursday, May 12, 2011.

    About Winner Medical:Winner Medical is a leading medical disposable products manufacturer in China, with business operations consisting of manufacturing, researching, developing and marketing cotton-based medical dressings and medical disposables, as well as consumer products. The Company has fourteen wholly-owned operating subsidiaries and three joint ventures, which manufacture tailored medical disposables and dressings, as well as non-woven fabric made from 100% natural cotton.  With a vertically integrated supply chain ranging from spinning fabric to finished goods, the Company provides its customers with a wide range of products, from surgical and wound care to consumer. The Company sells and markets its medical products and 100% natural cotton non-woven jumbo rolls in China and abroad. For nine consecutive years, the Company has been ranked as one of the top medical dressing exporters in China, with the United States, Europe, China and Japan being its most important markets. In addition, the Company distributes finished cotton non-woven consumer products under its own "PurCotton" brand name in China. With more than 20 years of international experience in the medical dressings and disposables field, the Company has a deep market understanding. This provides Winner Medical with a solid foundation, upon which it plans to expand by growing its medical grade 100% cotton retail business. To learn more about Winner Medical, please visit Winner Medical's web site at: http://winnermedical.investorroom.com

    Forward-Looking Statements:This press release contains certain statements that may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding Winner Medical and its subsidiary companies' business strategy, plans and objective and statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although Winner Medical believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Winner Medical's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in Winner Medical's periodic reports that are filed with and available from the Securities and Exchange Commission (the "SEC"). All forward-looking statements attributable to Winner Medical or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, Winner Medical does not assume a duty to update these forward-looking statements.

    Non-GAAP Financial MeasuresNon-GAAP net income and non-GAAP net income per basic and diluted share represent net income and net income per basic and diluted share before non-cash share-based compensation expenses and realized loss on commodity financial instruments. The Company believes its presentation of these non-GAAP measures provides meaningful insight into its operating performance and an alternative perspective on the results of operations. The Company believes that non-GAAP net income and net income per basic and diluted share are useful to both management and investors in evaluating the Company's operating performance compared with that of other companies in its industry. The calculation of non-GAAP net income and net income per basic and diluted share allows the Company to compare its operating results with those of other companies without giving effect to non-cash share-based compensation expenses and realized loss on commodity financial instruments, which may vary from different companies for reasons unrelated to the overall operating performance of a company's business.

    Non-GAAP net income are not measures of performance under accounting principles generally accepted in the United States (U.S. GAAP). The Company includes them in this Form 10-Q in order to:

  • improve transparency for investors;

  • assist investors in their assessment of the Company's performance;

  • facilitate comparisons to historical performance;

  • ensure that these measures are fully understood in light of how the Company evaluates its operating results; and

  • properly define the metrics used and confirm their calculation.

  • The non-GAAP measures provided herein may not be comparable to similar measures presented by other companies. The Company recognizes that the usefulness of non-GAAP net income and net income per basic and diluted share has certain limitations, including:

  • non-GAAP net income and net income per basic and diluted share do not include non-cash share-based compensation expenses and realized loss on commodity financial instruments. Because the Company periodically has granted, and expects to continue to grant, options and restricted share awards to its employees, share-based compensation expense is a necessary element of the Company's costs and ability to generate profits and cash flows. Also, because the Company periodically has engaged in futures trading to manage the impact of volatility in cotton prices on production, gains and losses on commodity financial instruments affect the Company's ability to generate net income. Therefore, any measure that excludes non-cash share-based compensation expenses and realized loss on commodity financial instruments may have material limitations; and

  • the manner in which the Company calculates non-GAAP net income and net income per basic and diluted share may differ from that of other companies, which limits their usefulness as a comparative measure.

  • The Company compensates for the foregoing limitations by using non-GAAP net income and net income per basic and diluted share as comparative tools, together with U.S. GAAP measurements, to assist in the evaluation of its operating performance.

    These non-GAAP results should not be regarded as a substitute for corresponding U.S. GAAP measures, but instead utilized as a supplemental measure of operating performance in evaluating the Company's business. As such, these non-GAAP measures should be viewed in conjunction with both the Company's financial statements prepared in accordance with U.S.GAAP. Please refer to the reconciliation of these supplemental non-GAAP financial measures to the most closely related U.S. GAAP measures provided for each period presented the "Management's Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures" section of the quarterly report on Form 10-Q for the reporting period ended March 31, 2011, as filed with the SEC on May 11, 2011.

    For more information, please contact:
    Company:
    Ms. Huixuan Chen (Fiona)
    Investor Relations Manager
    Winner Medical Group Inc.
    Tel:   +86-755-2806-6858
    +86-755-2813-8888 x691
    Email: investors@winnermedical.com
    Web:   http://ir.winnermedical.com
    Investors:
    Mr. Scott Powell
    HC International, Inc.
    Tel:   +1-212-301-7130
    Email: scott.powell@hcinternational.net
    Web:   http://www.hcinternational.net Winner Medical Group Inc.

    Consolidated Statements of Income and Comprehensive IncomeThree months ended March 31Six months ended March 312011201020112010US$US$US$US$Net sales33,218,003

    26,074,92766,924,320

    55,861,732Cost of sales(23,865,795)

    (18,718,742)(48,091,101)

    (39,073,700)Gross profit9,352,208

    7,356,18518,833,219

    16,788,032Other operating income, net593,133

    48,6241,112,261

    489,087Realized loss on commodity financial instruments(1,577,325)

    -(1,759,669)

    -Exchange difference, net(26,346)

    (55,801)(144,131)

    (80,181)Selling, general and administrative expenses(5,801,733)

    (4,139,927)(11,857,799)

    (9,463,646) 

      

     Income from operations2,539,937

    3,209,0816,183,881

    7,733,292Interest income11,627

    9,87146,168

    27,743Interest expense(47,899)

    (44,657)(93,185)

    (98,503)Equity in earnings of 50 percent or less owned persons 101,83375,347183,11745,025Income before income taxes2,605,498

    3,249,6426,319,981

    7,707,557Income taxes(348,710)

    (620,209)(722,396)

    (1,202,096)Net income2,256,788

    2,629,433

    5,597,585

    6,505,461Net (income)/loss attributable to non-controlling interests(20,851)

    47,105(33,404)

    91,789Net income attributable to

    Winner Medical Group Inc.2,235,937

    2,676,538

    5,564,181

    6,597,250Comprehensive income:Net income2,256,788

    2,629,4335,597,585

    6,505,461Foreign currency translation difference1,116,731

    24,8582,371,400

    (148,066)Comprehensive (income)/loss attributable to

      non-controlling interests(20,791)

    47,215(33,780)

    91,950Comprehensive income attributable toWinner Medical Group Inc.3,352,728

    2,701,506

    7,935,205

    6,449,345Net income attributable to

    Winner Medical Group Inc.  per share - basic0.09

    0.120.23

    0.29- diluted0.09

    0.120.23

    0.29Weighted average common stock outstanding- basic 24,130,247

    22,363,740 24,123,266

    22,363,740 - diluted24,533,132

    22,805,030

    24,534,405

    22,639,131 Winner Medical Group Inc.

    Consolidated Balance SheetsMarch 31September 3020112010US$US$ASSETSCurrent assets:Cash and cash equivalents11,994,114

    14,818,179Restricted bank deposits102,718

    285,119Restricted broker margin account1,278,754

    -Held-to-maturity investments-

    1,497,607Accounts receivable, less allowances for doubtful accounts of US$202,667 and US$230,200 at March 31, 2011 and September 30, 2010, respectively15,667,561

    15,672,446Amounts due from affiliated companies200,797

    999Inventories26,490,755

    15,945,101Prepaid expenses and other current assets12,111,786

    6,929,066Income taxes recoverable-

    33,974Deferred tax assets378,868

    428,741Total current assets68,225,353

    55,611,232Property, plant and equipment, net61,920,026

    60,110,367Investment in equity investees2,142,901

    2,159,784Intangible assets, net116,125

    125,079Prepaid expenses and other receivables 1,552,205

    637,748Deferred tax assets792,340

    331,785Total assets134,748,950

    118,975,995LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Short-term bank loans5,338,295

    -Accounts payable6,196,214

    5,362,155Accrued payroll and employee benefits2,512,175

    2,393,700Customer deposits1,495,112

    687,275Accrued and other liabilities2,748,419

    3,057,445Amounts due to affiliated companies125,027

    58,338Income taxes payable1,897,650

    1,477,212Total current liabilities20,312,892

    13,036,125Deferred tax liabilities43,641

    42,699Total liabilities20,356,533

    13,078,824Commitments and contingencies-

    -Stockholders' equity:Common stock, par value $0.001 per share;

    authorized 247,500,000, issued and

    outstanding March 31, 2011 –24,130,247 shares; September 30, 2010 –23,950,740 shares24,13123,951Additional paid-in capital40,680,575

    40,154,494Retained earnings54,294,215

    48,730,034Statutory reserves4,585,731

    4,585,731Accumulated other comprehensive income 14,673,786

    12,302,762Total Winner Medical Group Inc. stockholders' equity114,258,438

    105,796,972Non-controlling interests133,979

    100,199   Total equity114,392,417

    105,897,171Total liabilities and equity134,748,950118,975,995 Winner Medical Group Inc.

    Non-GAAP ReconciliationThree Months ended
    March 31 Six Months ended
    March 31 2011201020112010US$US$US$US$Net income attributable to Winner Medical Group Inc. (GAAP)

    2,235,937

    2,676,5385,564,181

    6,597,249Share-based compensation244,955

    244,215526,261

    547,118Realized Loss on Commodity Financial Instruments

    1,340,726

    -1,495,719

    -Adjusted net income attributable to Winner Medical Group Inc. (Non-GAAP)

    3,821,618

    2,920,7537,586,161

    7,144,367Earnings per share (GAAP)- Basic0.09

    0.120.23

    0.29- Diluted0.09

    0.120.23

    0.29Adjusted earnings per share (Non-GAAP)- Basic0.16

    0.130.31

    0.32- Diluted0.16

    0.130.31

    0.32Weighted average ordinary shares outstanding- Basic24,130,247

    22,363,74024,123,266

    22,363,740- Diluted24,533,132

    22,805,03024,534,405

    22,639,131Three Months ended
    March 31 Six Months ended
    March 31 2011201020112010US$US$US$US$Selling, general and administrative expenses (GAAP)

    5,801,733

    4,139,92611,857,799

    9,463,646Share-based compensation244,955

    244,215526,261

    547,118Adjusted selling, general and administrative expenses (Non-GAAP)

    5,556,778

    3,895,71111,331,538

    8,916,528
    '/>"/>

    SOURCE Winner Medical Group Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Winner Medical Group Inc. to Host Second Quarter 2011 Earning Conference Call on Wednesday, May 11, 2011 at 08:30 a.m. EDT
    2. Winner Medical Exhibited its PurCotton Retail Products at MICF 2011 in Beijing
    3. UBM Canon and Medical Design Excellence Awards (MDEA) Announce Winner of Lifetime Achievement Award
    4. Ferring Celebrates Winners of 2010 My Little Miracle Essay Contest During National Infertility Awareness Week
    5. Winner Medical to Attend 65th CMEF Spring11 Exhibition in Shenzhen
    6. Winner Medical Attending INDEX 11 Exhibition in Geneva
    7. Winner Medical CEO Awarded and Appointed Position by CNITA
    8. Winner Medical Wins the Circular Economy Project Award
    9. Oconee Medical Center is Winner of Siemens Who Inspires You? Video Contest
    10. Winner Medical to Attend Investor Conferences in March
    11. NorTech, Crains Cleveland Business Announce 2011 Innovation Award Winners
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
    (Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
    (Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
    (Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
    (Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
    (Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
    (Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
    Breaking Medicine News(10 mins):